TY  - GEN
AU  - Coiffier,Bertrand
AU  - Osmanov,Evgenii A
AU  - Hong,Xiaonan
AU  - Scheliga,Adriana
AU  - Mayer,Jiri
AU  - Offner,Fritz
AU  - Rule,Simon
AU  - Teixeira,Adriana
AU  - Walewski,Jan
AU  - de Vos,Sven
AU  - Crump,Michael
AU  - Shpilberg,Ofer
AU  - Esseltine,Dixie-Lee
AU  - Zhu,Eugene
AU  - Enny,Christopher
AU  - Theocharous,Panteli
AU  - van de Velde,Helgi
AU  - Elsayed,Yusri A
AU  - Zinzani,Pier Luigi
TI  - Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial
SN  - 1474-5488
PY  - 2011///1005
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antibodies, Monoclonal, Murine-Derived
KW  - administration & dosage
KW  - Antineoplastic Agents
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - therapeutic use
KW  - Boronic Acids
KW  - Bortezomib
KW  - Disease-Free Survival
KW  - Female
KW  - Humans
KW  - Infusion Pumps
KW  - Lymphoma, Follicular
KW  - drug therapy
KW  - Male
KW  - Middle Aged
KW  - Neoplasm Staging
KW  - Pyrazines
KW  - Recurrence
KW  - Rituximab
KW  - Young Adult
N1  - Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1016/S1470-2045(11)70150-4
ER  -